Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase

Maria Fuller, Ans Van Der Ploeg, Arnold J J Reuser, Donald S. Anson, John J. Hopwood

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Glycogenosis type II (GSD II, Pompe disease) is an autosomal recessive lysosomal storage disease that results from a deficiency of acid α‐glucosidase (GAA). Patients with this disorder are unable to break down lysosomal glycogen, which consequently accumulates in the lysosome, To evaluate enzyme replacement therapy for GSD II patients, we have expressed human GAA cDNA in Chinese hamster ovary‐K1 cells utilising a vector that places the cDNA under the transcriptional control of the human polypeptide chain elongation factor 1α gene promoter. A clonal cell line that secreted precursor recomibinant GAA at approximately 18 mg · 1−1 day−1 was identified. The precursor recombinant GAA was purified to homogeneity, had a molecular mass of 110 kDa as measured by SDS/PAGE, and was shown to have pH optima and kinetic parameters similar to those of GAA purified from human tissues. The partial N‐terminal amino acid sequence of recombinant GAA conformed to that derived from the nucleotide sequence of the cloned cDNA. The recombinant enzyme was taken up by cultured fibroblasts and skeletal muscle cells from GSD II patients, and was shown to correct the storage phenotype. Endocytosed GAA was localised to the lysosome and showed evidence of intracellular processing to a more mature form. Activity levels increased up to twice the normal value and uptake was prevented if cells were cultured in the presence of mannose 6‐phosphate.

LanguageEnglish
Pages903-909
Number of pages7
JournalEuropean Journal of Biochemistry
Volume234
Issue number3
DOIs
Publication statusPublished - 1995

Keywords

  • acid α‐glucosidase
  • enzyme replacement therapy
  • glycogenosis type II
  • lysosomal storage disorder
  • recombinant lysosomal enzyme

ASJC Scopus subject areas

  • Biochemistry

Cite this

Fuller, Maria ; Van Der Ploeg, Ans ; Reuser, Arnold J J ; Anson, Donald S. ; Hopwood, John J. / Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase. In: European Journal of Biochemistry. 1995 ; Vol. 234, No. 3. pp. 903-909.
@article{ba15572162b9489190d3cd0ac6d7d791,
title = "Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase",
abstract = "Glycogenosis type II (GSD II, Pompe disease) is an autosomal recessive lysosomal storage disease that results from a deficiency of acid α‐glucosidase (GAA). Patients with this disorder are unable to break down lysosomal glycogen, which consequently accumulates in the lysosome, To evaluate enzyme replacement therapy for GSD II patients, we have expressed human GAA cDNA in Chinese hamster ovary‐K1 cells utilising a vector that places the cDNA under the transcriptional control of the human polypeptide chain elongation factor 1α gene promoter. A clonal cell line that secreted precursor recomibinant GAA at approximately 18 mg · 1−1 day−1 was identified. The precursor recombinant GAA was purified to homogeneity, had a molecular mass of 110 kDa as measured by SDS/PAGE, and was shown to have pH optima and kinetic parameters similar to those of GAA purified from human tissues. The partial N‐terminal amino acid sequence of recombinant GAA conformed to that derived from the nucleotide sequence of the cloned cDNA. The recombinant enzyme was taken up by cultured fibroblasts and skeletal muscle cells from GSD II patients, and was shown to correct the storage phenotype. Endocytosed GAA was localised to the lysosome and showed evidence of intracellular processing to a more mature form. Activity levels increased up to twice the normal value and uptake was prevented if cells were cultured in the presence of mannose 6‐phosphate.",
keywords = "acid α‐glucosidase, enzyme replacement therapy, glycogenosis type II, lysosomal storage disorder, recombinant lysosomal enzyme",
author = "Maria Fuller and {Van Der Ploeg}, Ans and Reuser, {Arnold J J} and Anson, {Donald S.} and Hopwood, {John J.}",
year = "1995",
doi = "10.1111/j.1432-1033.1995.903_a.x",
language = "English",
volume = "234",
pages = "903--909",
journal = "European Journal of Biochemistry",
issn = "0014-2956",
publisher = "Wiley-Blackwell",
number = "3",

}

Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase. / Fuller, Maria; Van Der Ploeg, Ans; Reuser, Arnold J J; Anson, Donald S.; Hopwood, John J.

In: European Journal of Biochemistry, Vol. 234, No. 3, 1995, p. 903-909.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase

AU - Fuller, Maria

AU - Van Der Ploeg, Ans

AU - Reuser, Arnold J J

AU - Anson, Donald S.

AU - Hopwood, John J.

PY - 1995

Y1 - 1995

N2 - Glycogenosis type II (GSD II, Pompe disease) is an autosomal recessive lysosomal storage disease that results from a deficiency of acid α‐glucosidase (GAA). Patients with this disorder are unable to break down lysosomal glycogen, which consequently accumulates in the lysosome, To evaluate enzyme replacement therapy for GSD II patients, we have expressed human GAA cDNA in Chinese hamster ovary‐K1 cells utilising a vector that places the cDNA under the transcriptional control of the human polypeptide chain elongation factor 1α gene promoter. A clonal cell line that secreted precursor recomibinant GAA at approximately 18 mg · 1−1 day−1 was identified. The precursor recombinant GAA was purified to homogeneity, had a molecular mass of 110 kDa as measured by SDS/PAGE, and was shown to have pH optima and kinetic parameters similar to those of GAA purified from human tissues. The partial N‐terminal amino acid sequence of recombinant GAA conformed to that derived from the nucleotide sequence of the cloned cDNA. The recombinant enzyme was taken up by cultured fibroblasts and skeletal muscle cells from GSD II patients, and was shown to correct the storage phenotype. Endocytosed GAA was localised to the lysosome and showed evidence of intracellular processing to a more mature form. Activity levels increased up to twice the normal value and uptake was prevented if cells were cultured in the presence of mannose 6‐phosphate.

AB - Glycogenosis type II (GSD II, Pompe disease) is an autosomal recessive lysosomal storage disease that results from a deficiency of acid α‐glucosidase (GAA). Patients with this disorder are unable to break down lysosomal glycogen, which consequently accumulates in the lysosome, To evaluate enzyme replacement therapy for GSD II patients, we have expressed human GAA cDNA in Chinese hamster ovary‐K1 cells utilising a vector that places the cDNA under the transcriptional control of the human polypeptide chain elongation factor 1α gene promoter. A clonal cell line that secreted precursor recomibinant GAA at approximately 18 mg · 1−1 day−1 was identified. The precursor recombinant GAA was purified to homogeneity, had a molecular mass of 110 kDa as measured by SDS/PAGE, and was shown to have pH optima and kinetic parameters similar to those of GAA purified from human tissues. The partial N‐terminal amino acid sequence of recombinant GAA conformed to that derived from the nucleotide sequence of the cloned cDNA. The recombinant enzyme was taken up by cultured fibroblasts and skeletal muscle cells from GSD II patients, and was shown to correct the storage phenotype. Endocytosed GAA was localised to the lysosome and showed evidence of intracellular processing to a more mature form. Activity levels increased up to twice the normal value and uptake was prevented if cells were cultured in the presence of mannose 6‐phosphate.

KW - acid α‐glucosidase

KW - enzyme replacement therapy

KW - glycogenosis type II

KW - lysosomal storage disorder

KW - recombinant lysosomal enzyme

UR - http://www.scopus.com/inward/record.url?scp=0029559330&partnerID=8YFLogxK

U2 - 10.1111/j.1432-1033.1995.903_a.x

DO - 10.1111/j.1432-1033.1995.903_a.x

M3 - Article

VL - 234

SP - 903

EP - 909

JO - European Journal of Biochemistry

T2 - European Journal of Biochemistry

JF - European Journal of Biochemistry

SN - 0014-2956

IS - 3

ER -